Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study경증/일반 COVID-19 감염에서 클로로퀸 대 로피나비르/리토나비르의 효능: 전향적, 공개 표지, 다기관, 무작위 대조 임상 연구Study Protocol Published on 2020-07-082022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] adage calculated caused Chain Reaction China Chinese Chloroquine Chloroquine phosphate clinical clinical recovery clinical study Comparisons completion control group COVID-19 COVID-19 infection drugs effective antiviral treatment Efficacy and safety eligible experiment fluorescent Follow-up follow-up period help hospitals IMPROVE include Infection Lopinavir Lopinavir/ritonavir multicenter negativity normal temperature Open-label outbreak participant Patient patients with COVID-19 performed phosphate plan polymerase chain polymerase chain reaction Primary outcome Randomized Randomized controlled clinical study Randomly Recovery time registry reverse transcription Ritonavir RT-PCR Safe SARS-CoV-2 secondary outcome Secondary outcomes Serious Adverse Event Serious Adverse Events statistical significance level temperature tested therapeutic potential therapy throat-swab treat Treatment treatment period Trial two-sided test two-sided tests with COVID-19 [DOI] 10.1186/s13063-020-04478-w PMC 바로가기 [Article Type] Study Protocol
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and PerspectivesReview Published on 2020-06-302022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] acute respiratory syndrome Antiviral antiviral drug association China clinician coronavirus COVID-19 current described drug Efficacy Evidence guideline identify International Laboratory life-threatening Lopinavir Lopinavir/ritonavir MERS Middle East ongoing trial organ damage pandemic randomized clinical trial randomized trial recommendation recommendations Respiratory illness review Ritonavir role SARS searched syndrome Treatment viral replication viral-induced website Wuhan [DOI] 10.3390/jcm9072050 PMC 바로가기 [Article Type] Review
Treatment strategies of hospitalized patients with coronavirus disease-19Research Paper Published on 2020-06-302022-10-28 Journal: Aging (Albany NY) [Category] COVID-19, SARS, [키워드] Antiviral treatment Arbidol case sery China Combination coronasvirus disease-19 Coronavirus disease-19 COVID-19 Critical Critical disease diagnosed discharge rate discharged disease epidemiological and clinical characteristics Final Follow-up glucocorticoid Hospital stay hospitalized patient infected patients Lopinavir median Mild outbreak outside Wuhan oxygen Patient patients phosphate Prognosis retrospective single-center Support Transmission Treatment strategies Ventilation Wuhan [DOI] 10.18632/aging.103370 PMC 바로가기 [Article Type] Research Paper
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trialLetter Published on 2020-06-032022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 95% confidence interval Adjusted analysis Administered Admission age alcohol allocation concealment ALT/AST Analysis Arm arrhythmia assigned Beta block-randomization Blood calculated Care center clinical Clinical improvement clinical trial conducted confirmed case control group cough COVID-19 COVID-19 confirmed patient COVID-19 in patient COVID-2019 Cox proportional-hazards model death discharge disease dissemination drug Duration education Effectiveness element eligibility enrolled excluded exclusion criteria fatigue follow-up time hazard headache Health hospital hospital discharge Hospitalization Hydroxychloroquine + Lopinavir/Ritonavir improvement include Interaction Interferon beta-1a Interferon-β 1a Interferon-β 1b intervals intervention group investigator Kaletra Kaplan–Meier laboratory result lactating women Last limit log-rank test Loghman Hakim Hospital Lopinavir Lopinavir/ritonavir masking mechanical ventilation Medical Science Medical Sciences moderate Mortality myalgia nasal NCT04343768 number objective open label Open-label Other outcome oxygen saturation package parallel group participant Patient performed positive pregnant Primary outcome primary outcome measure problem professional protocol pulse-oximetry R software R version 3.6.1 randomization randomization sequence Randomized Randomized controlled trial Randomly reached receive Recigen recruitment refusal regimen Registered Research respiratory rate RT-PCR test Sample SARS-CoV-2 sealed secondary secondary outcome seven-category ordinal scale single center single dose SpO2 sputum production standard care status Study protocol Symptom temperature tested the patient therapeutic three groups time treat treated treatment groups Trial university version 3.6.1 website World Health Organization Ziferon [DOI] 10.1186/s13063-020-04382-3 PMC 바로가기 [Article Type] Letter
Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progressionArticle Published on 2020-06-012023-07-13 Journal: International Journal of Infectious Diseases [Category] SARS, [키워드] 2019-Coronavirus disease asymptomatic infection eosinophil Lopinavir [DOI] 10.1016/j.ijid.2020.03.013 PMC 바로가기
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/RitonavirMedicine Published on 2020-05-192022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] Admission caused COVID-19 Cruise ship diagnosed Elderly patient elderly patients hyponatremia Japan Lopinavir Lopinavir/ritonavir novel nucleic acid occurred outbreak Patient Pneumonia positive result respiratory Ritonavir RT-PCR Spread treated university Wuhan, China [DOI] 10.3389/fmed.2020.00241 PMC 바로가기 [Article Type] Medicine
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial중증 COVID-19 성인에 대한 렘데시비르: 무작위, 이중 맹검, 위약 대조, 다기관 시험Randomized Controlled Trial Published on 2020-05-162022-09-11 Journal: Lancet (London, England) [Category] SARS, 비임상, [키워드] Academy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adult patients Adverse adverse event adverse events Analysis animal models antiviral drug arterial oxygen partial pressure assigned Beijing breath China Chinese clinical benefits Clinical improvement clinical status concomitant use confirmation coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 defined development discharged double-blind effective Eligible patients Emergency enrolled enrolment event faster followed by fractional inspired oxygen GS-5734 hazard ratio hospital human coronaviruses in vitro inhibit inhibitory effect Inhibitory effects intention-to-treat interferons Intravenous remdesivir ITT ITT population laboratory-confirmed SARS-CoV-2 infection less Lopinavir Lopinavir-ritonavir Medical Science Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus multicentre nucleoside one patient Ordinal Scale oxygen oxygen partial pressure oxygen saturation partial pressure pathogenic Patient Placebo placebo group placebo recipients placebo-controlled Pneumonia primary analysis primary endpoint Program randomisation randomised Randomly receiving recipient reduction in Registered Remdesivir reported research and development respiratory respiratory syndrome coronavirus Ritonavir room air safety analysis SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication Science severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 statistically significant symptom duration symptom onset technology the placebo group those receiving placebo treated Treatment treatment group Trial Volume was done [DOI] 10.1016/S0140-6736(20)31022-9 PMC 바로가기 [Article Type] Randomized Controlled Trial
The Rationale for Potential Pharmacotherapy of COVID-19Review Published on 2020-05-142022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] ACE2 active against addition Antiviral Baricitinib Care cause Chloroquine clinical care Clinical management clinical trial clinical trials Clinical use Compound computational analysis Consensus coronavirus disease coronavirus epidemics Coronavirus infection coronavirus SARS-CoV-2 COVID-19 COVID-19 patient COVID-19 patients defined effective Epidemiology Evidence Favipiravir Health include increasingly Infection interferons investigated Lopinavir medication MERS-CoV Middle East molecular biology technique other disease pandemic pharmacological treatment pharmacotherapy Potential potential therapies professional Randomized rationale Remdesivir respiratory syndrome coronavirus SARS-CoV SARS-CoV-2 shown Spread Standard of care suggested tested Therapies therapy TMPRSS2 virus World Health Organization Wuhan, China [DOI] 10.3390/ph13050096 PMC 바로가기 [Article Type] Review
Quadruple therapy for asymptomatic COVID-19 infection patientsArticle Published on 2020-05-032023-06-15 Journal: Expert review of anti-infective therapy [Category] MERS, SARS, [키워드] Adverse drug reaction Arbidol Asymptomatic COVID-19 IFN-α Lopinavir Ritonavir [DOI] 10.1080/14787210.2020.1758066 PMC 바로가기
Clinical management of COVID-19Review Article Published on 2020-05-012023-06-15 Journal: The Indian journal of medical research [Category] MERS, SARS, [키워드] Clinical management Corticosteroids COVID-19 Hydroxychloroquine Lopinavir Remdesivir risk groups SARS-CoV-2 [DOI] 10.4103/ijmr.IJMR_957_20 PMC 바로가기 [Article Type] Review Article